Published in Breast Cancer Res Treat on June 26, 2013
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. Oncologist (2015) 0.86
Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol (2014) 0.81
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma? Breast J (2015) 0.80
Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors. Transl Oncol (2016) 0.78
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence. Expert Rev Mol Diagn (2014) 0.78
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. J Natl Compr Canc Netw (2015) 0.78
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. BMC Cancer (2016) 0.77
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer (2017) 0.77
Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med (2016) 0.75
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Oncotarget (2016) 0.75
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC Cancer (2017) 0.75
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 2.80
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg (2008) 1.73
The influence of a gene expression profile on breast cancer decisions. J Surg Oncol (2009) 1.52
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat (2011) 1.46
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health (2010) 1.40
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer (2010) 1.23
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst (2011) 1.23
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract (2011) 1.21
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist (2011) 0.94
Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm. Am Surg (2008) 0.91
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol (2003) 2.22
D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res (2013) 2.05
Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie (2006) 1.90
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol (2009) 1.80
Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol (2006) 1.74
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol (2012) 1.66
Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study. Am J Clin Oncol (2011) 1.54
Prenatal diagnosis in Li-Fraumeni syndrome. J Pediatr Hematol Oncol (2004) 1.47
Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol (2005) 1.45
Intraoperative radiotherapy for breast cancer. Isr Med Assoc J (2012) 1.41
[Do Norwegian cancer patients receive the care they deserve?]. Tidsskr Nor Laegeforen (2006) 1.39
Metastatic tumors to the jaws: a report of eight new cases. Med Oral Patol Oral Cir Bucal (2006) 1.12
The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med (2013) 1.10
Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res (2015) 1.09
Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol (2010) 1.01
Reducing health disparities: strategy planning and implementation in Israel's largest health care organization. Health Serv Res (2011) 0.99
Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer (2008) 0.93
[The quality indigators program in Clalit Health Services: the first decade]. Harefuah (2010) 0.92
Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol (2007) 0.91
Disseminated intravascular coagulation at presentation of advanced gastric cancer. Isr Med Assoc J (2006) 0.89
Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns (2012) 0.88
Attitudes of patients with gynecological and breast cancer toward integration of complementary medicine in cancer care. Int J Gynecol Cancer (2012) 0.87
Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol (2010) 0.87
Early exposure to a clinical oncology course during the preclinical second year of medical school. Acad Med (2015) 0.86
Wheatgrass in Afifi's garden: sprouting integrative oncology collaborations in the Middle East. J Clin Oncol (2011) 0.86
Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat (2010) 0.86
Association between bone mineral density and incidence of breast cancer. PLoS One (2013) 0.86
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis. PLoS One (2013) 0.84
Antipsychotics and diabetes: an age-related association. Ann Pharmacother (2008) 0.84
Integrating complementary medicine and supportive care: patients' perspectives toward complementary medicine and spirituality. J Altern Complement Med (2012) 0.83
Barriers to integration of traditional and complementary medicine in supportive cancer care of arab patients in northern Israel. Evid Based Complement Alternat Med (2011) 0.83
Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys. Leuk Lymphoma (2004) 0.82
Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy. J Pain Symptom Manage (2011) 0.82
The prognostic importance of cathepsin D and E-cadherin in early breast cancer: A single-institution experience. Oncol Lett (2011) 0.82
Prostasin, a potential tumor marker in ovarian cancer--a pilot study. Clinics (Sao Paulo) (2009) 0.82
Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women. Isr Med Assoc J (2002) 0.82
Breast cancer in octogenarians. Cancer (2006) 0.82
Reduction in sex-based mortality difference with implementation of new cardiology guidelines. Am J Med (2008) 0.81
[Integrating complementary medicine in oncology supportive care: assessment of patients' needs and expectations during chemotherapy]. Harefuah (2011) 0.81
Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients. Am J Clin Oncol (2009) 0.81
Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care (2007) 0.80
Twelve-year follow-up of a population-based primary care diabetes program in Israel. Int J Qual Health Care (2011) 0.80
Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. Anticancer Res (2009) 0.80
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. Isr Med Assoc J (2002) 0.80
Chemotherapy-related cognitive impairment: does integrating complementary medicine have something to add? Review of the literature. Breast Cancer Res Treat (2012) 0.79
Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Oncologist (2012) 0.79
Oncogenes in male breast cancer. Am J Clin Oncol (2003) 0.77
Analysis of memory deficits following chemotherapy in breast cancer survivors: evidence from the doors and people test. J Psychosoc Oncol (2011) 0.76
Cell-free DNA blood levels in colorectal cancer patients do not correlate with mismatch repair-proficiency. In Vivo (2014) 0.76
Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr Med Assoc J (2005) 0.76
The preoperative neutrophil/lymphocyte ratio does not correlate with the 21-gene recurrence score in estrogen receptor-positive breast cancer patients. Oncol Res Treat (2015) 0.76
Statins, aspirin and risk of venous thromboembolic events in breast cancer patients. J Thromb Thrombolysis (2014) 0.76
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. PLoS One (2013) 0.75
Malignant ascites and bacterial peritonitis. Med J Aust (2006) 0.75
[The effect of the introduction of pneumococcal vaccination for adults as a quality measure on vaccination rates in Clalit Health Services]. Harefuah (2011) 0.75
[Cancer-related lymphedema in Israel]. Harefuah (2008) 0.75
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups. Am J Clin Oncol (2002) 0.75
[Modeling integrative oncology care program for Arab patients in north Israel: towards quality of life improvement during chemotherapy]. Harefuah (2015) 0.75
Postoperative loco-regional radiation therapy for breast cancer patients with four or more involved lymph nodes or extracapsular extension. Isr Med Assoc J (2005) 0.75
[OUTCOMES OF HEPATIC, PANCREATIC AND GASTRIC SURGERY IN THE ELDERLY POPULATION: MORBIDITY, MORTALITY AND RESPONSE TO ONCOLOGIC TREATMENT]. Harefuah (2015) 0.75
FDG PET/CT differentiating two malignant tumors in the same patient. Acta Oncol (2011) 0.75
[Intraoperative radiotherapy (IORT) in early breast cancer]. Harefuah (2014) 0.75
The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology (2014) 0.75
Hand-assisted laparoscopic surgery for liver tumors. Isr Med Assoc J (2010) 0.75
Chronic myelogenous leukemia diagnosed in two patients with breast cancer. Leuk Lymphoma (2011) 0.75
Differences in pathological and clinical features of breast cancer in Arab as compared to Jewish women in Northern Israel. Int J Cancer (2011) 0.75
Breast cancer in Bedouin-Arab patients in southern Israel: epidemiologic and biologic features in comparison with Jewish patients. Asian Pac J Cancer Prev (2014) 0.75
Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity. Med Oncol (2003) 0.75
High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer. Am J Clin Oncol (2004) 0.75
Marketing of a new non-sedating antihistamine (fexofenadine) puts an additional burden on healthcare system resources in Israel. Eur J Gen Pract (2006) 0.75